Molecularly-Targeted Cancer Therapy is Here Why is Change So Hard?

Slides:



Advertisements
Similar presentations
Understanding Private Payers & Maximizing Private Payer Reimbursement Strategies: Understanding the Process Barbara Grenell, Preferred Health Strategies.
Advertisements

Code Blue Why are Costs so High? Chapters 8 through 14.
Value & Coverage Issue Brief Slides A Closer Look at Health Plan Coverage Policies and Approaches.
The US Healthcare System (There’s a hole in the bucket!) John C. Nelson, MD, MPH.
Certified Medical Coders (CMC) translate clinical data from patient health records and assign appropriate medical codes. Their work is submitted to.
All Payer Claims Database APCD Databases created by state mandate, that includes data derived from medical, eligibility, provider, pharmacy and /or dental.
Clarity, consent and coverage for research-related injuries 6 th Annual Columbia University IRB Conference Boston, MA Patrick Taylor Children’s Hospital.
The 70-Gene Profile and Chemotherapy Benefit in 1,600 Breast Cancer Patients Bender RA et al. ASCO 2009; Abstract 512. (Oral Presentation)
GENE THERAPY Presented at Paradoxes Sunday School Class, Sierra Madre Congregational Church, June 27, 2004.
Cancer Treatment from the DNA Perspective
The Social Transformation of American Medicine James G. Anderson, Ph.D. Purdue University.
Clarity, consent and coverage for research-related injuries 6 th Annual Columbia University IRB Conference Boston, MA Patrick Taylor Children’s Hospital.
Personalized Medicine
Chapter 4. Describe the history and evolution of health care information systems from the 1960s to the present. Identify the major advances in information.
Cancer Clinical Trials: The Basics. 2 What Are Cancer Clinical Trials? Research studies involving people Try to answer scientific questions and find better.
1 Reimbursing Health Care Providers It is all about striking the right balance between economic incentives for over-treatment and under- treatment Yaseen.
User Instruction: Patient Beginnings. Adding Patients Adding Payers Private Insurance Medicare/Medicaid Workers Comp Personal Injury.
1 Managed Care Digest Series ®, © 2013 sanofi-aventis U.S., A SANOFI COMPANY Data source: IMS Health © 2013 US.NMH Practice and Hospital Site.
Fees and costs in health care Elisabeth Barry Resolution Officer Health Care Complaints Commission.
March Sliding Fee Scales, Patients Cap on Charges Eli Camhi, MSSW – Tom Hickey -
How Available is Healthcare Principles of Health Science.
Best Practices in Financial Management Presented by: Teri U. Guidi, MBA, FAAMA President Oncology Management Consulting Group.
The Role of Personalized Medicine in our Future Delivery System Moderator: Edward Abrahams, Ph.D., President, Personalized Medicine Coalition Panelists:
INSURANCE & COSTS HEALTH CARE SERVICES. MEDICAL CARE (INSURANCE) HEALTH MAINTANCE ORGANIZATION (HMO) – A TYPE OF GROUP HEALTH INSURANCE PLAN – MEDICAL.
Medicare Unit 7. Medicare Part A Payment Plan Beneficiary Pays (2009) Hospital Stays 1-60 days $ days $267/day days $534/day 151+ days.
Heinrich & Corless Laboratories GIST Research Updates: May 2011.
Note: PCMH = patient-centered medical home; APCP = advanced primary care practice. Source: The Commonwealth Fund/Kaiser Family Foundation 2015 National.
 Who will you bill?  How will you bill?  How do you decide how much to bill?  What else?
National Leader The state of Maryland, hospitals, and insurance companies partnered Applied to the federal government for a 5 year “demonstration project”
2010 Pay for Performance (P4P) Program Training for Participants.
Clarifying the Regulatory Framework of Off-Label Usage Institute for International Research Washington, DC July 17, 2002 Reimbursement for Off-Label Uses.
Medication Therapy Management Programs in Community Pharmacy Community Pharmacy October 17, 2006 Kurt A. Proctor, Ph.D., RPh Chief Operating Officer Community.
Medicare Part A Payment Plan Beneficiary Pays (2004) Hospital Stays 1-60 days$ days$210/day days$420/day 151+ daysall costs SNF 1-20 daysnothing.
SOURCE: The Kaiser Family Foundation/Commonwealth Fund 2015 National Survey of Primary Care Providers (conducted January 5 – March 30, 2015) Primary Care.
Use of Oncotype Dx® Testing Breast SSG meeting 10 th July 2015 Dr Rebecca Bowen.
Total Cost of Care Reporting Jim Chase Health Care Financing Task Force October 2, 2015.
Ethical issues with the regulatory use of gene expression data Benjamin S Wilfond MD Medical Genetics Branch National Human Genome Research Institute Department.
22 CHAPTER PUBLIC SECTOR ECONOMICS: The Role of Government in the American Economy Randall Holcombe Health Care.
Source: National Association of Health Underwriters Education Foundation State of U.S. Healthcare 1.
Jan 2002 EDMA The central role of the Medical Laboratory in a World of Managed Health An EDMA presentation of the benefits of in vitro testing as a basis.
Understanding Community Cancer Care.  Historically, cancer care occurred predominantly in hospital setting  A few decades ago, care migrated to the.
City of Frederick Board of Aldermen Meeting October 27, 2010 FCAA/City of Frederick FQHC Planning Project.
Real World Evidence in Cancer Care: A Payer’s Perspective CADTH SYMPOSIUM 2016 Scott Gavura, Director, Provincial Drug Reimbursement Programs.
Genotyping and Genomic Profiling of Non– Small-Cell Lung Cancer: Implications for Current and Future Therapies Tianhong Li, Hsing-Jien Kung, Philip C.
Comorbidity and Multimorbidity: Measurement and Interventions Holly M. Holmes, MD, MS Dept of General Internal Medicine.
Is the $1000 Genome as Near as We Think
Gene Editing Opportunity for Accelerating Gain
Hereditary Cancer Predisposition: Updates in Genetic Testing
THE ROLE OF NEXT GENERATION SEQUENCING IN CLINICAL PRACTICE
On Human Gene Editing: International Summit Statement
Description of Project
Clinical Leadership Decision Process
The Nurse View: Management of Pancreatic Cancer
Children’s National Health System ICEOS 2016 – Utrecht, Holland
HOW TO WORK THE ACCOUNTS OUT OF TICKLER
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Content and Labeling of Tests Marketed as Clinical “Whole-Exome Sequencing” Perspectives from a cancer genetics clinician and clinical lab director Allen.
Positive Impacts of Developing Novel Endpoints Generated by Mobile Technology for Use in Clinical Trials* SPECIFIC BENEFITS   SHORT-TERM MEDIUM-TERM LONG-TERM.
Figure 5 Schematic illustration of different clinical trial designs
Oncology Care Model 2.0 The Universal Payment Model in Oncology
Applying Genomics to Daily Clinical Practice Current Status and Major Challenges Michael Seiden M.D. Ph.D.
Figure 3 Summary of overall survival by Kaplan–Meier
Clinical Research Association TURKEY
Coverage and Reimbursement to Genetic Testing
PROSTATE CANCER CIRCULATING BIOMARKER CONSENSUS STATEMENT QUESTIONS
Physicians Are More Satisfied with Private Insurers Than Medicare and Medicaid on Payment and Administrative Burden Among physicians: In general, how would.
Figure 1 Overview of the imaging biomarker roadmap
Session 3: Coverage and Reimbursement for Genetic Testing
Variation Across Payers
Overall Survival and Progression-free Survival
Presentation transcript:

Molecularly-Targeted Cancer Therapy is Here Why is Change So Hard?

Advances in DNA Sequencing Technologies We can sequence DNA 1,000 times faster than just a few years ago, for about the same cost The technology is robust and highly reproducible between laboratories Instead of testing 1 to 3 genes in a cancer, we are now testing at a time Sequencing all 20,000 genes in the genome is being performed in some labs and will become commonplace in the near future

Clinical Utility of Broad-based DNA Sequencing in Cancer Our lab conducted a recent study of 301 cases of advanced cancer: A 37-gene panel was completed on all cases The results influenced patient care in ~20% of cases New options included: Entry into a clinical trial Use of a targeted therapy off-label In some cases, a decision not to use a particular therapy J Clin Oncol 32:5s, 2014 (suppl; abstr 11028)

Costs and Reimbursements The cost for sequencing a panel of 37 genes is only ~4 times the cost of sequencing 1 gene Most private insurers are reimbursing at ~40-50% of charges, but some pay nothing However, 45% of patients with the most common cancers are on Medicare In the eyes of Medicare, only half a dozen genes are relevant to cancer and only these are being paid New billing codes for gene panels have been created but are not assigned any $$ value

Summary There is an enormous and growing gap between what technology can deliver and what is accepted by payers as ‘standard of care’ Opportunities to benefit patients with common cancers (e.g. lung cancer) are being missed throughout the country Laboratories that strive to make state-of-the-art testing available are being financially penalized The FDA has announced it will begin to regulate all laboratory-developed tests in the U.S., which will add to costs and overall regulatory burden